The reduction is modest and routine for a passive manager; no change in investment thesis is signaled. Monitor future 13G filings to see if the trend continues toward the 5% threshold.
VTRS drugs
VTRS drug pipeline →Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
T. Rowe Price Associates filed an amended Schedule 13G disclosing a 5.1% passive stake in Viatris as of September 30, 2026, down from 6.3% in the prior filing 10 days ago. The reduction is modest and consistent with routine portfolio rebalancing by a passive investment manager.
Key Financial Metrics
Key Facts
- T. Rowe Price Associates reported beneficial ownership of 58,912,075 shares of Viatris common stock as of September 30, 2026.
- The stake represents 5.1% of shares outstanding, down from 6.3% in the prior SC 13G/A filed November 6, 2026.
- The filing is a passive investor update under Rule 13d-1(b); T. Rowe Price disclaims beneficial ownership and intent to influence control.
- The reduction of approximately 1.2 percentage points is within normal range for a passive manager's portfolio adjustments.
Financial Impact
T. Rowe Price reduced its stake by approximately 1.2 percentage points, from 6.3% to 5.1% of Viatris shares outstanding.
Risk Factors
- Further reductions could bring the stake below 5%, triggering a potential exit signal.
- The filing does not disclose the reason for the reduction; it may reflect fund flows or rebalancing rather than a view on Viatris.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G/A Filing (Primary) | 0000080255-26-000718 |
| Document: 0000080255-26-000718-index.html | 0000080255-26-000718 |
| Document: 0000080255-26-000718.txt | 0000080255-26-000718 |
Track record
22 reports on VTRS
3 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +16.85% at T+60 after the Aug 6, 2026 report. 7 of 9 went positive at some point.
Filters
- Nov 17, 2026today 8-K Neutral 4/10 Entry $20.51 Now $20.49 −0.10% settles Feb 16
- Nov 17, 2026today Press Release Neutral 4/10 Entry $20.89 Now $20.49 −1.91% settles Feb 16
- Nov 16, 20261d ago SC 13G/A Neutral 2/10 Viewing Entry $20.84 Now $20.49 −1.68% settles Feb 12
- Nov 6, 202611d ago SC 13G/A Neutral 2/10 Entry $19.91 Now $20.49 +2.91% settles Feb 4
- Nov 5, 202612d ago 8-K Mixed 6/10 Entry $18.97 Now $20.49 +8.01% settles Feb 3
- Nov 4, 202613d ago Press Release Neutral 2/10 Entry $19.22 Now $20.49 +6.61% settles Feb 2
- Oct 30, 202618d ago Press Release Bullish 6/10 Entry $19.04 Now $20.49 +7.64% settles Jan 28
- Oct 29, 202619d ago Institutional Cluster Bullish 4/10 Entry $19.20 Now $20.49 +6.72% settles Jan 27
- Oct 16, 20264w ago Press Release Bullish 6/10 Entry $18.26 Now $20.49 +12.21% settles Jan 14
- Oct 8, 20265w ago 8-K Bullish 7/10 Entry $17.44 Now $20.49 +17.49% settles Jan 5
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers